Pharming Group (NASDAQ:PHAR) Trading 4.4% Higher – Still a Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR)’s stock price was up 4.4% on Wednesday . The stock traded as high as $17.32 and last traded at $17.55. Approximately 5,296 shares traded hands during trading, a decline of 49% from the average daily volume of 10,425 shares. The stock had previously closed at $16.81.

Analyst Upgrades and Downgrades

Several research analysts recently commented on PHAR shares. Zacks Research raised shares of Pharming Group from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 6th. Wall Street Zen upgraded Pharming Group to a “strong-buy” rating in a report on Saturday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pharming Group in a report on Monday, December 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $38.00.

Pharming Group Price Performance

The company has a market cap of $1.19 billion and a PE ratio of -1,738.26. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The firm has a 50 day simple moving average of $16.08 and a 200-day simple moving average of $13.82.

Pharming Group (NASDAQ:PHAR) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. As a group, research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC bought a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.